OK-101 first-in-human Phase 2 trial will incorporate primary and secondary efficacy endpoints characterizing signs and symptoms of Dry Eye Disease-
Omega Diagnostics Gp (AIM:ODX) Positive WHO data received for VISITECT® CD4 test
Test shows high diagnostic accuracy (specificity and sensitivity)
OKYO Pharma (NASDAQ: OKYO; LSE: OKYO) Interview to Air on Bloomberg U.S. on the RedChip Money Report®
NEW YORK and LONDON, Sept. 08, 2022 (GLOBE NEWSWIRE) — OKYO Pharma Limited (NASDAQ: OKYO; LSE: OKYO;), a biotechnology company focused on the discovery and development of novel molecules to
Omega Diagnostics Gp (AIM:ODX) Change of preliminary results date
Change of preliminary results date and investor presentation and update to CD4 sale
Omega Diagnostics Gp (AIM:ODX) Completion of Sale of the CD4 Business
Completion of Sale of the CD4 Business
Sareum Holdings PLC (AIM:SAR) CTA application to MHRA and Corporate Update
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
Omega Diagnostics Heads of Terms agreed for Sale of CD4 Busines
Omega Diagnostics Group PLC, (AIM: ODX). announced that it has selected a preferred bidder for its CD4 business after having made an announcement nearly two months back.
Omega Diagnostics Gp (AIM:ODX) Result of Open Offer
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health products, announces the results of its Open Offer.
Omega Diagnostics Gp (AIM:ODX) Placing, Subscription and Open Offer
Placing of 50,000,000 New Ordinary Shares and Warrants
Omega Diagnostics Gp (AIM:ODX) Trading Update
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, provides the following trading update for the year ended
Omega Diagnostics Gp (AIM:ODX) Result of Open Offer
Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Health & Nutrition and Global Health (CD4 and COVID-19) products, today announces the results of its Open Offer.
OKYO Pharma LTD (AIM: OKYO) announces issuance of U.S. Patent No. 11,254,720
Covering OKYO’s dry eye drug candidate OK-101 for use to treat ocular neuropathic pain.